Artiva Biotherapeutics, Inc. 4

RA Capital Management, L.P. and affiliates reported the grant of a director stock option for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of about $10.42 per share, held by director Laura Stoppel for the benefit of RA Capital’s funds.

On September 10, 2026, RA Capital Management, L.P. and affiliated reporting persons disclosed the award of a director stock option covering 16,250 shares of Artiva Biotherapeutics, Inc. common stock to Laura Stoppel in connection with her service on the company’s board, with an exercise price of approximately $10.42 and an expiration date of September 9, 2036; the option vests on the earlier of September 10, 2027 or the 2027 annual stockholder meeting, and is held by Dr. Stoppel for the benefit of RA Capital’s funds and a managed account pursuant to an arrangement under which any net proceeds upon exercise are turned over to the adviser, with the reporting persons disclaiming beneficial ownership except to the extent of their pecuniary interest.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001231919-26-001173

Alert Tier

5